PL3204030T3 - Terapia skojarzona zakażenia hbv i hdv - Google Patents
Terapia skojarzona zakażenia hbv i hdvInfo
- Publication number
- PL3204030T3 PL3204030T3 PL15775453.2T PL15775453T PL3204030T3 PL 3204030 T3 PL3204030 T3 PL 3204030T3 PL 15775453 T PL15775453 T PL 15775453T PL 3204030 T3 PL3204030 T3 PL 3204030T3
- Authority
- PL
- Poland
- Prior art keywords
- hbv
- combined therapy
- hdv infection
- hdv
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Rectifiers (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14187865 | 2014-10-07 | ||
| PCT/EP2015/073173 WO2016055534A2 (en) | 2014-10-07 | 2015-10-07 | Combination therapy of hbv and hdv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3204030T3 true PL3204030T3 (pl) | 2022-09-19 |
Family
ID=51790567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15775453.2T PL3204030T3 (pl) | 2014-10-07 | 2015-10-07 | Terapia skojarzona zakażenia hbv i hdv |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180228804A1 (pl) |
| EP (2) | EP3204030B1 (pl) |
| KR (2) | KR20230156963A (pl) |
| CN (2) | CN107106686B (pl) |
| CA (3) | CA3175236C (pl) |
| EA (1) | EA201790786A1 (pl) |
| ES (1) | ES2922883T3 (pl) |
| PL (1) | PL3204030T3 (pl) |
| PT (1) | PT3204030T (pl) |
| SI (1) | SI3204030T1 (pl) |
| WO (1) | WO2016055534A2 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2917231T3 (da) | 2012-11-12 | 2019-06-11 | Univ Heidelberg Ruprecht Karls | Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme |
| EP3463422B1 (en) * | 2016-05-30 | 2024-05-22 | Shanghai Hep Pharmaceutical Co., Ltd. | Compositions and methods for treating metabolic diseases |
| EP3392267A1 (en) * | 2017-04-18 | 2018-10-24 | Myr GmbH | Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors |
| CN109718364A (zh) * | 2017-10-27 | 2019-05-07 | 上海贺普药业股份有限公司 | 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法 |
| JPWO2019139126A1 (ja) * | 2018-01-11 | 2021-04-08 | 国立大学法人 東京大学 | Ntcp阻害剤 |
| EP4157327A4 (en) * | 2020-05-28 | 2024-11-27 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF SARS-COV-2 INFECTIONS |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116510021A (zh) * | 2022-01-24 | 2023-08-01 | 上海贺普药业股份有限公司 | 有限化慢性乙肝的核苷(酸)类药物治疗的药物及方法 |
| WO2025240242A1 (en) * | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) * | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2315405T3 (es) * | 2001-05-25 | 2009-04-01 | Dobeel Corp. | Proteina pre-s del virus de la hepatitis b (vhb) como adyuvante y un componente de una vacuna frente a vhb. |
| WO2009092396A1 (en) * | 2008-01-25 | 2009-07-30 | Universitätsklinikum Heidelberg | Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| EP2245047B1 (en) * | 2008-01-25 | 2020-11-18 | Ruprecht-Karls-Universität Heidelberg | Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as vehicles for the specific delivery of compounds to the liver |
| WO2013159243A1 (en) * | 2012-04-25 | 2013-10-31 | National Institute Of Biological Sciences, Beijing | Compositions and uses of functional receptor for hbv/hdv virus |
| DK2917231T3 (da) * | 2012-11-12 | 2019-06-11 | Univ Heidelberg Ruprecht Karls | Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme |
-
2015
- 2015-10-07 EP EP15775453.2A patent/EP3204030B1/en active Active
- 2015-10-07 PT PT157754532T patent/PT3204030T/pt unknown
- 2015-10-07 CA CA3175236A patent/CA3175236C/en active Active
- 2015-10-07 CA CA3175242A patent/CA3175242A1/en active Pending
- 2015-10-07 CN CN201580054357.0A patent/CN107106686B/zh active Active
- 2015-10-07 US US15/514,878 patent/US20180228804A1/en not_active Abandoned
- 2015-10-07 CN CN202211229195.8A patent/CN115920061A/zh active Pending
- 2015-10-07 WO PCT/EP2015/073173 patent/WO2016055534A2/en not_active Ceased
- 2015-10-07 CA CA2959465A patent/CA2959465C/en active Active
- 2015-10-07 KR KR1020237038014A patent/KR20230156963A/ko not_active Withdrawn
- 2015-10-07 SI SI201531861T patent/SI3204030T1/sl unknown
- 2015-10-07 PL PL15775453.2T patent/PL3204030T3/pl unknown
- 2015-10-07 KR KR1020177007068A patent/KR102599942B1/ko active Active
- 2015-10-07 EP EP22169956.4A patent/EP4098273A1/en active Pending
- 2015-10-07 EA EA201790786A patent/EA201790786A1/ru unknown
- 2015-10-07 ES ES15775453T patent/ES2922883T3/es active Active
-
2021
- 2021-03-23 US US17/209,615 patent/US20220040178A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230156963A (ko) | 2023-11-15 |
| CN107106686B (zh) | 2022-09-27 |
| CA3175242A1 (en) | 2016-04-14 |
| WO2016055534A3 (en) | 2016-06-09 |
| CA2959465C (en) | 2024-05-21 |
| WO2016055534A2 (en) | 2016-04-14 |
| EP3204030A2 (en) | 2017-08-16 |
| US20220040178A1 (en) | 2022-02-10 |
| US20180228804A1 (en) | 2018-08-16 |
| CA3175236A1 (en) | 2016-04-14 |
| PT3204030T (pt) | 2022-08-05 |
| CA2959465A1 (en) | 2016-04-14 |
| KR20170066339A (ko) | 2017-06-14 |
| ES2922883T3 (es) | 2022-09-21 |
| CN107106686A (zh) | 2017-08-29 |
| EP3204030B1 (en) | 2022-04-27 |
| KR102599942B1 (ko) | 2023-11-09 |
| SI3204030T1 (sl) | 2022-10-28 |
| EA201790786A1 (ru) | 2017-09-29 |
| CA3175236C (en) | 2025-10-14 |
| EP4098273A1 (en) | 2022-12-07 |
| CN115920061A (zh) | 2023-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301322I2 (nl) | Repotrectinib en/of farmaceutisch aanvaardbare zouten daarvan | |
| IL280905A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| PL3402888T3 (pl) | Środki i sposoby leczenia hbv | |
| IL262301A (en) | Liposomal preparation and methods of treatment | |
| IL258147A (en) | Combination therapy of an hbv capsid assembly inhibitor and an interferon | |
| LT3684377T (lt) | Hepatito b infekcijos gydymo būdai | |
| LT3179991T (lt) | Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai | |
| EP3875139C0 (en) | TREATMENT OF VENOUS DISEASES | |
| IL257663B (en) | Oral care compositions and methods of use | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| EP4212536C0 (en) | BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | |
| PL3204030T3 (pl) | Terapia skojarzona zakażenia hbv i hdv | |
| DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
| HRP20181130T1 (hr) | Postupci za liječenje infekcija virusom filoviridae | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| LT3277842T (lt) | Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| IL251505A0 (en) | Neuroactive compounds and methods of use thereof | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| PL3362084T3 (pl) | Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania | |
| LT3341027T (lt) | Transfekcijos kompleksai ir jų panaudojimo būdai | |
| DK3204497T3 (da) | Terapeutisk hæmning af lactatdehydrogenase og midler dertil | |
| EP3212170C0 (en) | IMPLANTABLE MEDICAL DEVICES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS | |
| DK3237621T3 (da) | Varianter af human alpha-galactosidase |